舍曲林治疗影响帕金森综合征的[18F]FE-PE2I PET显像
研究基于4例每日服用舍曲林且[18F]FE-PE2I PET表现不典型的患者,在停用舍曲林5天后重新扫描,发现舍曲林对尾状核SBR有显著影响(p=0.029),呈线性剂量依赖关系。作者建议在[18F]FE-PE2I PET检查时考虑舍曲林的影响,尤其是全局性结合降低的患者,若可耐受应考虑暂停舍曲林,特别是剂量高于50 mg/天时。
要点
- 舍曲林对[18F]FE-PE2I PET尾状核SBR有显著影响(p=0.029),呈线性剂量依赖关系。
- 每日50 mg舍曲林可使75 kg男性SBR降低0.32、65 kg女性降低0.44。
- 作者建议[18F]FE-PE2I PET检查时考虑舍曲林影响,若可耐受可考虑暂停(尤其>50 mg/天)。
核心结论
- 舍曲林与其他SSRI不同,对DaT有高亲和力,会影响[18F]FE-PE2I PET结果,导致纹状体结合全局性降低。
- 作者建议在[18F]FE-PE2I PET检查时考虑舍曲林治疗的影响,尤其是表现全局性PE2I结合降低的患者。
- 作者建议若可耐受,应考虑暂停舍曲林治疗,特别是剂量高于50 mg/天时。
研究设计与样本
- 对4例有每日舍曲林使用史且[18F]FE-PE2I PET表现不典型的患者,在停用舍曲林5天后重新行[18F]FE-PE2I PET扫描。
- 根据体重和剂量估算舍曲林血浆浓度,采用尾状核特异性结合比值(SBR)评估对示踪剂结合的影响。
- 与1例在停用莫达非尼7天前后行[18F]FE-PE2I PET的患者进行比较。
主要发现
- 舍曲林对尾状核SBR有显著影响(p=0.029)。
- 该影响呈线性剂量依赖关系:每日50 mg舍曲林时,75 kg男性SBR降低0.32,65 kg女性SBR降低0.44。
关键数值与推荐
- 舍曲林对尾状核SBR影响显著(p=0.029)。
- 每日50 mg舍曲林对应SBR降低:75 kg男性降低0.32,65 kg女性降低0.44。
临床怎么用
- 作者建议[18F]FE-PE2I PET检查时考虑舍曲林治疗的影响,尤其是表现全局性PE2I结合降低的患者。
- 作者建议若可耐受,应考虑暂停舍曲林治疗,特别是剂量高于50 mg/天时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The dopamine transporter (DaT) PET ligand [18F]FE-PE2I is used to aid the diagnosis of Parkinson's disease. After encountering four patients with a history of daily sertraline use, who all showed atypical findings on [18F]FE-PE2I PET, we suspected that the selective serotonin reuptake inhibitor (SSRI), sertraline, might interfere with the results and lead to globally reduced striatal [18F]FE-PE2I binding due to sertraline's high affinity for DaT. METHODS: We rescanned the four patients with [18F]FE-PE2I PET after a 5-day sertraline pause. Sertraline plasma concentration was estimated based on body weight and dose, and specific binding ratios (SBR) in caudate nucleus, known to be more preserved in Parkinson's, were used to estimate the effect on tracer binding. Comparison was made to a patient with [18F]FE-PE2I PET before and after a 7-day Modafinil pause. RESULTS: We found a significant effect of sertraline on caudate nucleus SBR (p = 0.029). The effect showed a linear dose-dependent relationship that corresponds to a reduction in SBR by 0.32 or 0.44 for a 75 kg male or a 65 kg female, respectively, taking a daily dose of 50 mg sertraline. CONCLUSION: Sertraline is one of the most commonly used antidepressants and in contrast to other SSRI's, sertraline show high affinity for DaT. We recommend that sertraline treatment is taken into account when patients are undergoing [18F]FE-PE2I PET especially in patients showing apparent globally reduced PE2I binding. If tolerable, pausing of the sertraline treatment should be considered, especially for doses above 50 mg/day.
引用
- Justesen TEH, Borghammer P, Aanerud J, et al. Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism. EJNMMI Res. 2023. PMID: 37221321. doi:10.1186/s13550-023-01000-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。